Journal article

Histone deacetylase inhibitors in lymphoma and solid malignancies

Walid Rasheed, Mark Bishton, Ricky W Johnstone, H Miles Prince

EXPERT REVIEW OF ANTICANCER THERAPY | TAYLOR & FRANCIS LTD | Published : 2008

Abstract

Histone deacetylase inhibitors (HDACi) are a new class of antineoplastic agents with demonstrable preclinical antitumor activity in both in vitro and in vivo studies in a wide range of malignancies. Based on these preclinical findings, in recent years HDACi have undergone a rapid phase of clinical development with many HDACi entering Phase I-III clinical trials, both as single agents and in combination with other therapies. Favorable clinical responses have been demonstrated in cutaneous T-cell lymphoma with emerging evidence of clinical activity in other types of lymphoma and, to date, a good toxicity profile. Solid tumor responses to single agent and combination therapies have also been re..

View full abstract